Similarly, HMGB1 was also significantly increased in children with acute promyelocytic leukemia (APL), but in the treatment of APL, differentiation therapy based on all‐trans retinoic acid (ATRA) and arsenic trioxide could induce excessive inflammation and differentiation syndrome (DS),187 which results in fatal effects. The gene discussed is HMGB1; the disease is acute promyelocytic leukemia.